BIOVIE INC.
Beverly, Massachusetts, United States · Biotechnology, Health Care, Therapeutics
BioVie is pioneering an innovative technology
Key facts
- Headquarters
- Beverly, Massachusetts, United States
- Employees
- 20
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (BIVI)
- Website
- biovie.com
- Company page
Recent activity at BIOVIE INC.
- : SEC 8-K (1.01): On September 11, 2026, BioVie Inc. entered into a material definitive sales agreement with A.G.P./Alliance Global Partners, allowing the Company to issue and sell up to $6,464,341 in shares of its Class A common stock, par value $0.0001 per share. This agreement permits sales to be made from time to time to or through the Agent, utilizing the previously filed Registration Statement on Form S-3 (File No. 333-296924). The strategic implications of this agreement include enhanced capital raising capabilities, which could support the Company’s operational and growth initiatives.
- : SEC 8-K (7.01): On August 6, 2026, BioVie Inc. issued a press release regarding the results from its Phase 2 SUNRISE-PD trial, which is investigating the efficacy of its drug candidate bezisterim in patients with early-stage Parkinson's disease. The announcement outlines key findings from the trial, aiming to evaluate the potential impact of bezisterim on disease progression. The press release is included as Exhibit 99.1. This disclosure is significant as it highlights the company's ongoing research efforts and potential advancements in treatment options for Parkinson's disease, which could influence investor sentiment and stock performance.
- : SEC 8-K (5.02): On November 10, 2025, at BioVie Inc.'s annual meeting of stockholders, shareholders approved an amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance under the plan to 3,100,000. This change aims to enhance the Company’s ability to attract, retain, and provide incentives to its employees and directors, aligning their interests with those of stockholders. The amendment is effective immediately and corresponds with the ongoing need for equity compensation. The full terms of the amended plan are included in the Definitive Proxy Statement filed with the SEC on September 25, 2025.
- : SEC 8-K (5.07): On November 10, 2025, BioVie Inc. held its 2025 annual meeting of stockholders where significant corporate governance actions took place. Stockholders elected directors, including Amy Chappell and Cuong Do, for one-year terms set to expire at the next annual meeting. Out of 7,535,080 shares of Class A common stock outstanding, 3,417,857 shares were present either in person or through proxy, satisfying quorum requirements. The results showed a strong majority for the nominees, indicating shareholder confidence and strategic continuity in the company's leadership. This meeting and the consequent votes reflect the company's ongoing governance practices and stakeholder engagement efforts.
- : BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement
- : BIOVIE
- : BIOVIE INC.
- : BIOVIE INC.
- : BIOVIE INC.
BIOVIE INC. funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2022 | Venture | $6.0M |
| May 2017 | Venture | Undisclosed |
| Jan 2017 | Pre-Seed | $200K |
| Oct 2016 | Pre-Seed | $10K |
Leadership
- Sigmund Rogich, Director
- Robert Hariri, M.D., Ph.D., Director
- Steve Gorlin, Director
- Richard Berman, Director
- Michael Sherman, Director
- Jim Lang, Director
- Terren Peizer, Director
- Cuong Do, Executive Officer, Director
- Julie Anderson, Director
- James Lang, Director
Verified email and direct lines for BIOVIE INC.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
BIOVIE INC. in the news
- BioVie Inc. (BIVI) Stock Price, News, Quote & History - Yahoo! Finance Canada (Nov 01, 2026)
- Biovie seeks FDA meeting to plan Phase 3 trial for Parkinson’s drug candidate - Parkinson's News Today (Sep 10, 2026)
- BioVie Announces Update to Parkinson’s Phase 3 Development Program - GlobeNewswire (Sep 08, 2026)
- BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim - Yahoo Finance (Aug 06, 2026)
- BIVI Stock Slides As New Equity Offering Looms Over Traders - StocksToTrade (Aug 06, 2026)
- Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire (Jun 05, 2026)
- Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results - ACCESS Newswire (Sep 16, 2026)
- BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program - Fierce Biotech (Aug 06, 2026)
Companies similar to BIOVIE INC.
- Rejuvenation Technologies · Biotechnology, Health Care, Therapeutics
- Aerska · Biotechnology, Health Care, Therapeutics
- Lifesenz Cancer Research Labs Private Limited · Biotechnology, Health Care, Therapeutics
- Illimis Therapeutics · Biotechnology, Health Care, Therapeutics
- Tessera Defense & Homeland Security Inc. · Biotechnology, Health Care, Therapeutics
About BIOVIE INC.: questions and answers
What does BIOVIE INC. do?
BioVie is pioneering an innovative technology
Where is BIOVIE INC. headquartered?
BIOVIE INC. is headquartered in Beverly, Massachusetts, United States.
How many employees does BIOVIE INC. have?
BIOVIE INC. has about 20 employees.
Has BIOVIE INC. raised funding?
Yes. Fundz has recorded 4 funding events for BIOVIE INC.. The most recent, $6.0M, was in Jul 2022.
What is the latest news on BIOVIE INC.?
On Sep 11, 2026, SEC 8-K (1.01): On September 11, 2026, BioVie Inc. entered into a material definitive sales agreement with A.G.P./Alliance Global Partners, allowing the Company to issue and sell up to $6,464,341 in shares of its Class A common stock, par value $0.0001 per share. This agreement permits sales to be m
Is BIOVIE INC. a public company?
Yes. BIOVIE INC. is publicly traded under the ticker BIVI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy